Small molecule inhibitors of the VEGF and tyrosine kinase for the treatment of cervical cancer-Reference-Cited by-同舟云学术

Small molecule inhibitors of the VEGF and tyrosine kinase for the treatment of cervical cancer

Published:2024-07-10 Issue:8 Volume:41 Page:
ISSN:1559-131X
Container-title:Medical Oncology
language:en
Short-container-title:Med Oncol

Author:

Sarwar Fatima,Ashhad Samreen,Vimal Archana^ORCID,Vishvakarma Reena^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12032-024-02446-x.pdf

Reference103 articles.

1. Guimarães YM, Godoy LR, Longatto-Filho A, dos Reis R. Management of early-stage cervical cancer: a literature review. Cancers (Basel). 2022;14:575.

2. Eifel PJ, Klopp AH, Berek JS, Konstantinopoulos PA. Cancer of the cervix, vagina, and vulva. DeVita, Hellman, and Rosenberg’s cancer: principles & practice of oncology. Europe: Wolters Kluwer Health Pharma Solutions (Europe) Ltd; 2018. p. 1172–210.

3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

4. Tarver T. American cancer society. cancer facts and figures 2014. J Consumer Health Internet. 2012;16:366–7.

5. del Campo JM, Prat A, Gil-Moreno A, Pérez J, Parera M. Update on novel therapeutic agents for cervical cancer. Gynecol Oncol. 2008;110:S72–6.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent Treatment Strategies and Molecular Pathways in Resistance Mechanisms of Antiangiogenic Therapies in Glioblastoma;Cancers;2024-08-27